Connect with us

Cannabis

MustGrow Imports Bio-Pesticide into Colombia for Testing on “Panama Disease”: Existential Threat to Bananas

Newsfile

Published

on

 

  • National State of Emergency declared in Colombia.
  • Panama Disease is existential threat to global $25 billion banana industry.
  • Disease remains viable in soil for decades – no effective treatments currently available.
  • MustGrow’s natural bio-pesticide technology has shown 100% control of similar diseases.

Saskatoon, Saskatchewan–(Newsfile Corp. – June 16, 2020) – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company“, “MustGrow“), an agricultural biotech company developing and commercializing a portfolio of natural, science-based biological crop protection products, is pleased to announce the successful importation of its bio-pesticide TerraMG into Colombia. TerraMG is MustGrow’s signature mustard-derived bio-pesticide formulation that has been proven to control soil-borne pests and diseases.

Laboratory testing in Colombia will focus on eradicating the Panama Disease (Fusarium wilt TR4), a devastating disease pathogen ravaging the $25 billion global banana industry. MustGrow’s previous independent efficacy studies involving the treatment of Fusarium oxysporum, a soil-borne pathogen, have demonstrated 100% control of the fungus. Panama Disease is among the most destructive banana diseases, affecting particularly Cavendish bananas (half of all bananas produced). Currently, there are no effective treatments for infected banana plantations, with the disease remaining viable for decades in the soil and can cause 100% yield loss(1).

MustGrow has already been working towards its US-EPA and Canadian-PMRA registrations of TerraMG for pre-plant treatment of soil-borne pests and diseases in high value fruits & vegetables. Now, MustGrow is replicating that strategy in Colombia’s besieged banana industry – focused on controlling and eliminating the Panama Disease. This work will build on MustGrow’s existing field data and serve as a benchmark for achieving registration labels in Colombia and other leading South American agricultural countries.

“This is a huge milestone for MustGrow, as we expand our footprint from North America to South America.” Remarked MustGrow COO Colin Bletsky. “The Colombian government has declared a National State of Emergency, with no viable options available to combat Panama Disease – we look forward to potentially aiding not only Colombian farmers, but the health and prosperity of the nation itself.”

The spread of Panama Disease through banana plantations in South America has prompted Colombia to reportedly declare a National State of Emergency, enacting special measures to stop the disease from spreading, including the preventive eradication of 168 hectares of infected crop. A flurry of media reports has followed, revealing a race to save bananas from extinction after the disease has left a trail of scorched banana plantations in its wake.

(1) Source: http://www.fao.org

MustGrow has issued 100,000 common share purchase warrants (each a “Warrant“) to a consultant of the Company in connection with achievement of this importation milestone. Each Warrant shall entitle the consultant to acquire one common share of the Company at a price of $0.28 exercisable until June 15, 2022. The issuance is subject to CSE approval and all securities are subject to a four-month hold period.

About MustGrow

MustGrow is a publicly traded (CSE: MGRO) (OTCQB: MGROF) agriculture biotech company focused on providing natural science-based biological solutions for high value crops, including fruits & vegetables. MustGrow has designed and owns a United States EPA-approved natural solution that uses the mustard seed’s natural defence mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada’s PMRA (Pest Management Regulatory Agency) as a bio-pesticide for high value crops such as in fruit & vegetables. MustGrow has now concentrated a liquid format that with regulatory approval, could be applied through standard drip or spray equipment, improving functionality and performance features.

The Company has approximately 37 million basic common shares issued and outstanding. For further details please visit www.mustgrow.ca.

ON BEHALF OF THE BOARD

“Corey Giasson”

Director & CEO
Phone: +1-306-668-2652

Forward-Looking Statements

Certain statements included in this press release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”.

Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow.

These risks are described in more detail in MustGrow’s Prospectus and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities and available at www.sedar.com. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Important

Always read and follow label use directions. © 2020 MustGrow Biologics Corp. All rights reserved.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/57912

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Cannabis

Emerald Health Therapeutics Announces Stock Option Grant

Newsfile

Published

on

Vancouver, British Columbia–(Newsfile Corp. – August 3, 2020) – Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (“Emerald”) announces that it has issued an aggregate of 3,800,000 stock options to employees, consultants and directors at an exercise price of $0.21 per common share for a period of five years. All stock options will vest 25% on the date of grant and 25% on the first three anniversaries of the date of grant. Emerald has also granted an aggregate of 175,000 restricted share units to certain employees. The restricted share units will vest one year from the grant date and convert into common shares of Emerald at a fair market value of $0.21 per common share. The stock options and restricted share units have been granted pursuant to Emerald’s Omnibus Incentive Plan which has been previously approved by Emerald’s shareholders and the TSX Venture.

About Emerald Health Therapeutics

Emerald Health Therapeutics, Inc. is committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis and non-cannabis products, with an emphasis on life science-based innovation and production excellence. Emerald’s three distinct operating assets are designed to uniquely serve the Canadian marketplace and international opportunities. These assets, all in full production, include: its Metro Vancouver, BC-based greenhouse operation (78,000 square feet) capable of producing organic-certified product; Verdélite, its premium craft cannabis production indoor facility in St. Eustache, Québec (88,000 square feet); and Pure Sunfarms, its 41.3%-owned joint venture in Delta, BC, producing high quality, affordably priced products (1.1 M square feet). Its Emerald Naturals subsidiary has launched a new natural wellness product category with its non-cannabis endocannabinoid-supporting product line and is expanding distribution across Canada.

Please visit www.emeraldhealth.ca for more information or contact:

Jenn Hepburn, Chief Financial Officer
(800) 757 3536 Ext. #5

Emerald Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements.

We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, changes of law and regulations; changes of government; failure to obtain regulatory approvals or permits; failure to obtain necessary financing; results of production and sale activities; results of scientific research; regulatory changes; changes in prices and costs of inputs; demand for labour; demand for products; failure of counter-parties to perform contractual obligations; as well as the risk factors described in Emerald’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management’s current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. Emerald undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60965

Continue Reading

Cannabis

PAOG Outlines Strategic Next Steps and Corporate Housecleaning Agenda

Newsfile

Published

on

Sandusky, Ohio–(Newsfile Corp. – August 3, 2020) – PAO Group, Inc. (OTC Pink: PAOG) today released a letter from CEO James C. DiPrima to update shareholders on strategic next steps in addition to reviewing corporate housecleaning agenda items. The letter is included in its entirety below:

Cannot view this image? Visit: https://i2.wp.com/grassnews.net/wp-content/uploads/2020/08/paog-outlines-strategic-next-steps-and-corporate-housecleaning-agenda.jpg?w=740&ssl=1
PAOG New Logo

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6729/60946_7bc5829b742ca8b9_001full.jpg

Dear Shareholder,

The last three weeks have been busy for PAOG. Much has been accomplished – a management takeover, and two acquisitions. Expect the momentum to continue. Key contracts moving the company’s acquired cannabis biopharmaceutical technology forward are coming soon.

PAOG anticipates entering into a Contract Research Organization (CRO) agreement as a first step toward initiating an Investigational New Drug Application (IND) to ultimately achieve Food and Drug Administration (FDA) approval for its RespRx Chronic Obstructive Pulmonary Disease (COPD) treatment.

Based on positive results from an informal trial of RexpRX with 25 COVID-19 patients, PAOG also plans to make a Coronavirus Treatment Acceleration Program (CTAP) application after entering into a CRO agreement.

At the same time that we are advancing our cannabis biopharmaceutical technology, we also have some general housekeeping to catch up on. PAOG is behind on its reports required to maintain “current information” status with OTC Markets. We also need to update our website and contact information. We expect to complete all promptly.

A new website is now available. The site is preliminary. Look for continuous updates. Please sign-up for our newsletter and we’ll let you know when to check back.

You can find our new website at www.paogroupinc.com.

Thank you for your interest in our mission to advance the future of medical cannabis technology.

Best Regards,
James C. DiPrima

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Contact Us:
Jim DiPrima
888-272-6472
info@pao.group

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60946

Continue Reading

Cannabis

Spyder Cannabis Disclosure Update

Newsfile

Published

on

Vaughan, Ontario–(Newsfile Corp. – July 31, 2020) –  Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company“) provides an update to the filing of disclosure documents as a result of COVID-19:

Filing of Annual Disclosure Documents Due to COVID-19

In a press release dated June 25, 2020, the Company announced, among other things, that due to circumstances created by the COVID – 19 pandemic, it would not be filing its April 30, 2020 quarterly report and management discussion and analysis which was due June 29, 2020.

The Company reports that it has yet to file its April 30, 2020 quarterly report and management discussion and analysis to date.

About Spyder Cannabis Inc.

Spyder is a Cannabis, Vape and CBD retailer that operates in jurisdictions where the products are federally legal in both Canada and the United States. The Company, through its subsidiaries, is a retailer involved in the development of three retail business units. The first is the sale of Cannabis products, the second is the sale of CBD in the United States only, the third is the sale of smoking cessation products in Ontario.

Cautionary Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities laws (“forward-looking statements”). Forward- looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

For more information, please contact:

Spyder Cannabis Inc.
Dan Pelchovitz
President & Chief Executive Officer
Telephone: 1.888.504.7737
Email: corporate@spydercannabis.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60930

Continue Reading

Trending Online

Grassnews is part of PICANTE Media and Events, a leading media and boutique event organizer in the European Union with a monthly reach of +50,000 readers. The official company (PROSHIRT SRL), has been listed for 4 years in a row among the top 3 Advertising and market research agencies in the local Top Business Romania Microcompanies based on the Financial Reports. Grassnews digests / hand picks the latest news about the CBD / Legal Cannabis industry and serves them to you daily.

Contact us: sales@picante.today

Editorial / PR Submissions

© Grassnews .com 2019 - 2020 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania